|Bid||115.21 x 200|
|Ask||115.87 x 200|
|Day's Range||113.63 - 116.69|
|52 Week Range||94.42 - 127.64|
|PE Ratio (TTM)||43.45|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene stock dipped to a four-month low Monday after ozanimod failed to show a disability benefit over interferon in multiple sclerosis patients.
Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal in a second late-stage study, bringing the U.S. biotech a step closer to launching a potential blockbuster. The drug, ozanimod, reduced annualized relapse rate in patients with relapsing multiple sclerosis, compared to Biogen Inc's Avonex, the company said on Monday. Celgene's shares were marginally down in premarket trading.